| Impact of the primary tumor location on secondary sites and overall mortality in patients with metastatic upper tract urothelial carcinoma | | 2022 |
| Validation and Application of MD Anderson Symptom Inventory Module for Patients with Bladder Cancer in the Perioperative Setting | | 2022 |
| Resolution of the expert council “Modern options for the treatment of urothelial cancer” | | 2022 |
| Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis | | 2022 |
| Urethral Cancer After Urethroplasty: A Case Report and Review of the Literature | | 2022 |
| Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors | Urologic Oncology: Seminars and Original Investigations | 2022 |
| Reply to: Comments on "Neoadjuvant/Induction Combination Immunotherapy versus Combination Platinum‐based Chemotherapy for Locally Advanced (Stage III) Urothelial Cancer." | International Journal of Cancer | |
| The Impact of Neutrophil-to-Lymphocyte Ratio after Two Courses of Pembrolizumab for Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma | Biomedicines | 2022 |
| PET-CT in Clinical Adult Oncology—IV. Gynecologic and Genitourinary Malignancies | Cancers | 2022 |
| Insights on recent innovations in bladder cancer immunotherapy | Cancer Cytopathology | |
| Real‐world treatment patterns and clinical outcomes of Japanese patients with non‐muscle invasive bladder cancer receiving intravesical bacillus Calmette–Guérin treatment | International Journal of Urology | |
| Survival after Neoadjuvant/Induction Combination Immunotherapy versus Combination Platinum‐based Chemotherapy for Locally Advanced (Stage III ) Urothelial Cancer | International Journal of Cancer | |
| Adjuvant immunotherapy in patients with high-risk muscle-invasive urothelial carcinoma: The potential impact of informative censoring. | Cancer | 2022 |
| Cost-Effectiveness Analysis of Hepatic Arterial Infusion Chemotherapy of Infusional Fluorouracil, Leucovorin, and Oxaliplatin Versus Transarterial Chemoembolization in Patients With Large Unresectable Hepatocellular Carcinoma. | Frontiers in Pharmacology | 2022 |
| Head-to-Head Comparison of the Expression Differences of NECTIN-4, TROP-2, and HER2 in Urothelial Carcinoma and Its Histologic Variants. | Frontiers in Oncology | 2022 |
| MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. | Nature Communications | 2022 |
| Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder Cancer. | Cancers | 2022 |
| Management of Advanced Urothelial Carcinoma in Older and Frail Patients: Have Novel Treatment Approaches Improved Their Care? | Drugs and Aging | 2022 |
| Impact of neoadjuvant chemotherapy on survival and recurrence patterns after robot-assisted radical cystectomy for muscle-invasive bladder cancer: Results from the International Robotic Cystectomy Consortium. | International Journal of Urology | 2021 |
| Efficacy of Surgery on the Primary Tumour in Patients with Metastatic Bladder Cancer: A Comprehensive Review | Bladder Cancer | 2022 |
| Uptake of re-resection in T1 bladder cancer: An interrupted population-based time series analysis among different groups of surgeons. | Urologic Oncology: Seminars and Original Investigations | 2022 |
| Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day. | Biomedicines | 2022 |
| Digital ischaemia and necrosis from oxaliplatin. | BMJ Case Reports | 2022 |
| New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond. | Cells | 2022 |
| Neoadjuvant and Adjuvant Therapy for Muscle-Invasive Bladder Cancer | | 2022 |
| Impact of FDG- PET CT in the Management of Muscle Invasive Bladder Cancer. | Clinical Genitourinary Cancer | 2022 |
| Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis. | European Urology | 2022 |
| Re: Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study. | European Urology | 2022 |
| Management of Patients With Advanced Urothelial Carcinoma in an Evolving Treatment Landscape: A Qualitative Study of Provider Perspectives of First-Line Therapies. | Clinical Genitourinary Cancer | 2021 |
| A Prospective Study of a Resorbable Intravesical Fiducial Marker for Bladder Cancer Radiation Therapy. | Advances in Radiation Oncology | 2022 |
| Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials | European Urology | 2021 |
| Upper Tract Urothelial Carcinoma | | 2021 |
| Intravesical Therapy for Non-muscle Invasive Urothelial Carcinoma | | 2021 |
| Medical Oncology | | 2008 |
| Contemporary Trends and Efficacy of Pelvic Lymph Node Dissection at Radical Cystectomy for Urothelial and Variant Histology Carcinoma of the Urinary Bladder. | Clinical Genitourinary Cancer | 2021 |
| Latest progress in molecular biology and treatment in genitourinary tumours | Clinical and Translational Oncology | 2020 |
| Validity of using cancer registry data for comparative effectiveness research | | |
| Metastatic Nodal Pattern: Is There a Role for Paraaortic Lymph Node Dissection | | 2018 |
| Integrating chemotherapy and radiotherapy for bladder cancer | | |
| Impact of health services on compliance and outcomes | | |
| The Role of Lymphadenectomy in the Management of Urothelial Carcinoma of the Upper Urinary Tract | | 2015 |
| Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma | Clinical Genitourinary Cancer | 2021 |
| Oncological benefit of re-resection for T1 bladder cancer: a comparative effectiveness study | BJU International | 2021 |
| Cost-Effectiveness of Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma in the United States | Advances in Therapy | 2021 |
| Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for urothelial cell carcinoma of the urinary bladder 2017 | Urology Annals | 2018 |
| Prognostic role of delay before radical cystectomy: retrospective analysis of a single-centre cohort with 376 patients | Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology | 2018 |
| Treatment Sequencing Patterns in Patients with Metastatic Urothelial Cancer Treated in the Community Practice Setting in the United States: SPEAR-Bladder (Study informing treatment Pathway dEcision in bladder cAnceR) | ClinicoEconomics and Outcomes Research | 2020 |
| Incidence of upper tract urothelial carcinoma in Spain | Actas Urológicas Españolas | 2020 |
| Antibody-Drug Conjugates in Urothelial Carcinomas | Current Oncology Reports | 2020 |
| Treatment Overview | | 2017 |
| Postmarketing Cases of Enfortumab Vedotin-Associated Skin Reactions Reported as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis | JAMA Dermatology | 2021 |
| Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop | Nature Reviews Urology | 2021 |
| Updated pathology reporting standards for bladder cancer: biopsies, transurethral resections and radical cystectomies | World Journal of Urology | 2021 |
| A Rare Case Report of Metastatic Urothelial Carcinoma to Skull with Significant Reossification after Pembrolizumab | Medicina (Lithuania) | 2021 |
| Trimodality Therapy With or Without Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer | Clinical Genitourinary Cancer | 2021 |
| Real-world outcomes in locally advanced or metastatic urothelial carcinoma following platinum and PD-1/L1 inhibitor therapy | Future Oncology | 2021 |
| Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303 | Future Oncology | 2021 |
| Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer | International Journal of Urology | 2021 |
| Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial | European Urology | 2021 |
| Metastasis-directed radiation therapy after radical cystectomy for bladder cancer | Urologic Oncology: Seminars and Original Investigations | 2021 |
| Pitcher pot neourethral modification of ileal orthotopic neobladder achieves satisfactory long-term functional and quality of life outcomes with low clean intermittent self-catheterization rate. | BJUI Compass | 2021 |
| Immunotherapy in the Treatment of Urothelial Bladder Cancer: Insights From Single-Cell Analysis | Frontiers in Oncology | 2021 |
| p53 Expression, Programmed Death Ligand 1, and Risk Factors in Urinary Tract Small Cell Carcinoma | Frontiers in Oncology | 2021 |
| Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC | Journal of Cancer Research and Clinical Oncology | 2021 |
| Neoadjuvant vascular-targeted photodynamic therapy improves survival and reduces recurrence and progression in a mouse model of urothelial cancer | Scientific Reports | 2021 |
| The Factors Affecting Expansion of Reactive Tumor Infiltrating Lymphocytes (TIL) From Bladder Cancer and Potential Therapeutic Applications | Frontiers in Immunology | 2021 |
| Effect of intracorporeal urinary diversion on the incidence of benign ureteroenteric stricture after cystectomy | International Journal of Urology | 2021 |
| Perioperative therapy in muscle invasive bladder cancer | Indian Journal of Urology | 2021 |
| Utilization of systemic therapy for treatment of advanced urothelial carcinoma: Lessons from real world experience | Cancer Treatment and Research Communications | 2021 |
| Primary Small Cell Carcinoma of the Kidney: Disease Characteristics and Treatment Outcomes | Medicines (Basel, Switzerland) | 2021 |
| Bladder preserving chemoradiotherapy compared to surgery for variants of urothelial carcinoma and other tumors types involving the bladder: An analysis of the National Cancer Database | Clinical and Translational Radiation Oncology | 2021 |
| Effect of Treatment with the PD-1/PD-L1 Inhibitors on Key Health Outcomes of Cancer Patients | BioDrugs | 2021 |
| Ta grade 3/high grade non-invasive bladder cancer: Should we perform a second TUR? | International Journal of Clinical Practice | 2021 |
| Current Landscape and Future Directions on Bladder Sparing Approaches to Muscle-Invasive Bladder Cancer | Current Treatment Options in Oncology | 2020 |
| Trends in management of ureteral urothelial carcinoma and effects on survival: a hospital-based registry study | Urologic Oncology: Seminars and Original Investigations | 2021 |
| A review of upper urinary tract cytology performance before and after the implementation of The Paris System | Cancer Cytopathology | 2021 |
| Can random bladder biopsies be eliminated after bacillus Calmette-Guérin therapy against carcinoma in situ? | International Urology and Nephrology | 2021 |
| Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines | Oncologist | 2021 |
| "Real-world" outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma | Urologic Oncology: Seminars and Original Investigations | 2021 |
| Predicting risk of multiple levels of recurrence and progression after initial diagnosis of nonmuscle-invasive bladder cancer in a multisite, community-based cohort | Cancer | 2021 |
| Lymph node dissection for bladder cancer: Current standards and the latest evidence | International Journal of Urology | 2021 |
| Post-cystectomy Enterocele: A Case Series and Review of the Literature | Urology | 2021 |
| A patient with synchronous bilateral low-grade upper tract urothelial carcinoma who underwent nephroureterectomy and total ureterectomy with ileal ureteric replacement | International Cancer Conference Journal | 2020 |
| Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review | Diagnostics | 2020 |
| Recurrent Bladder Cancer in a Teenage Male | Urology | 2020 |
| Atezolizumab in patients with renal insufficiency and mixed variant histology: analyses from an expanded access program in platinum-treated locally advanced or metastatic urothelial carcinoma | | 2020 |
| Adherence to guideline recommendations for multimodality treatment of patients with pT2-3 M0 non-urothelial carcinoma of the urinary bladder: Temporal trends and survival outcomes | International Journal of Urology | 2020 |
| Shedding Light on Bladder Cancer Diagnosis in Urine | Diagnostics | 2020 |
| Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis | Journal of Clinical Medicine | 2020 |
| Somatic Testing and Germline Genetic Status: Implications for Cancer Treatment Decisions and Genetic Counseling | Current Genetic Medicine Reports | 2020 |
| Nephroureterectomy vs. segmental ureterectomy of clinically localized, high-grade, urothelial carcinoma of the ureter: Practice patterns and outcomes | Urologic Oncology: Seminars and Original Investigations | 2020 |
| Incidence of upper tract urothelial carcinoma in Spain | Actas Urológicas Españolas (English Edition) | 2020 |
| Radiation with concurrent radiosensitizing capecitabine tablets and single-dose mitomycin-C for muscle-invasive bladder cancer: A convenient alternative to 5-fluorouracil | Radiotherapy and Oncology | 2020 |
| A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer | Cancer | 2020 |
| Immune checkpoints and their inhibitors: Reappraisal of a novel diagnostic and therapeutic dimension in the urologic malignancies | Seminars in Oncology | 2020 |
| Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma | Research and Reports in Urology | 2020 |
| Micropapillary Versus Urothelial Carcinoma of the Urinary Bladder: Stage at Presentation and Efficacy of Chemotherapy Across All Stages-A SEER-based Study | European Urology Focus | 2021 |
| Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis | | 2020 |
| Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma | Drugs | 2020 |
| Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial | International Journal of Clinical Oncology | 2020 |
